Pfizer Announced on Friday that their COVID-19 antiviral pill reduced the risk of coronavirus hospitalizations and deaths by 89 percent compared to those given a placebo, according to an analysis of study data.
In a study that examined adults who had contracted COVID-19 and were considered to be at high risk of becoming seriously ill, the drug company reported that of 389 people who received the drug, 3 (.8 percent) were hospitalized, but not they died.
In this group, the patients had experienced symptoms for three days and were given a regimen of three pills, twice a day.
By comparison, 385 people received the placebo in this group, and 27 hospitalizations with 7 deaths were reported, according to the company.
Pfizer said study data showed that even when patients received the COVID-19 antiviral pill, called Paxlovid, within five days of symptoms onset, it was still effective.
In another group, the drug company studied those who received the treatment within five days of the onset of symptoms. The study showed that of 607 people who received the drug, six (1 percent) were hospitalized within 28 days, but no deaths were reported. Comparatively, of 612 people who received placebos, 41 people (6.7 percent) ended up in the hospital and 10 people died.
Pfizer said the study data would be sent to the Food and Drug Administration (FDA) as soon as possible, which would be included in its emergency use authorization request for the drug.
The study has not yet been peer-reviewed.
“Today’s news is a true game changer in global efforts to stem the devastation of this pandemic. These data suggest that our oral antiviral candidate, if approved or licensed by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations. ” said the CEO and president of Pfizer. Albert Bourla said in a statement.
Merck has also developed its own COVID-19 antiviral pill, called molnupiravir, which has also been shown to be effective in curbing COVID-19 hospitalizations.
The pill, developed in conjunction with Ridgeback Biotherapeutics, has been shown to reduce COVID-19 hospitalizations by 50 percent, Merck reported last month. In mid-October, the drug company said it had submitted an emergency use authorization request to the FDA.
If both pills are cleared for emergency use by the FDA, it would be considered another tool to help mitigate COVID-19.
Although President BidenJoe BidenHouse sets Friday’s voting for Biden’s agenda. House leaders make a last-minute change to drug prices after the dispute aide who traveled with Biden to Europe tests positive for COVID-19: inform MOREchief medical advisor Anthony FauciAnthony FauciNikki Haley Calls For A Cognitive Test For Older Politicians 12:30 PM Report From The Hill: Fauci Companies Post-Holiday Vaccination Mandate Criticizes Paul For Saying He Is Responsible For The COVID Pandemic MORE It previously warned that Merck’s drug should not be considered an alternative to the COVID-19 vaccine, as it could help alleviate the possibility of an increase in COVID-19 cases.